Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor PK/PD and Safety in Neonates at Risk of Thrombosis
NCT02765633Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2017
- Primary completion
- Aug 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cangrelor in thrombosis, sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Total plasma concentrations of cangrelor and its primary metabolite, AR C69712 at 8 hours, Proportion of participants achieving >=90% inhibition of final platelet aggregation at 1 hour and 2 more. Started Jan 2017; status: completed.
02
Drugs
cangrelor
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT02765633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765633.